300347 泰格医药
已收盘 12-23 15:00:00
资讯
新帖
简况
海金格IPO投研报告：CRO遇冷为何业绩逆势增长？北交所两问真实合理性
时代周报-时代在线 · 19:30
海金格IPO投研报告：CRO遇冷为何业绩逆势增长？北交所两问真实合理性
泰格医药控股子公司为其他控股孙公司提供担保
新浪港股 · 12-19
泰格医药控股子公司为其他控股孙公司提供担保
泰格医药(03347)控股子公司为其他控股孙公司提供担保
智通财经 · 12-18
泰格医药(03347)控股子公司为其他控股孙公司提供担保
泰格医药涨5.22%，开源证券一个月前给出“买入”评级
证券之星 · 12-06
泰格医药涨5.22%，开源证券一个月前给出“买入”评级
港股医药外包概念股集体冲高，药明康德(02359.HK)涨超10%，药明生物(02269.HK)涨超8%，昭衍新药(06127.
美港电讯 · 12-06
港股医药外包概念股集体冲高，药明康德(02359.HK)涨超10%，药明生物(02269.HK)涨超8%，昭衍新药(06127.
泰格医药（300347）12月5日主力资金净卖出498.45万元
证券之星 · 12-06
泰格医药（300347）12月5日主力资金净卖出498.45万元
泰格医药(03347)截至11月末累计回购365.52万股A股
智通财经 · 12-04
泰格医药(03347)截至11月末累计回购365.52万股A股
泰格医药：已回购365.52万股 成交总金额约1.91亿元
中国财富通 · 12-04
泰格医药：已回购365.52万股 成交总金额约1.91亿元
泰格医药(300347.SZ)累计回购365.52万股 耗资1.91亿元
智通财经 · 12-04
泰格医药(300347.SZ)累计回购365.52万股 耗资1.91亿元
泰格医药(03347)上涨5.14%，报34.75元/股
金融界 · 11-29
泰格医药(03347)上涨5.14%，报34.75元/股
港股生物医药股午后放量大涨，科伦博泰生物(06990.HK)张近10%，诺诚健华(09969.HK)涨超8.5%，百济神州(06160.
美港电讯 · 11-27
港股生物医药股午后放量大涨，科伦博泰生物(06990.HK)张近10%，诺诚健华(09969.HK)涨超8.5%，百济神州(06160.
泰格医药(03347)上涨5.25%，报34.1元/股
金融界 · 11-27
泰格医药(03347)上涨5.25%，报34.1元/股
泰格医药(03347)股价上升5.093%，现价港币$34.05
阿斯达克财经 · 11-27
泰格医药(03347)股价上升5.093%，现价港币$34.05
CRO概念股早盘回暖 金斯瑞生物科技涨逾4%泰格医药涨超3%
新浪港股 · 11-27
CRO概念股早盘回暖 金斯瑞生物科技涨逾4%泰格医药涨超3%
来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投
活报告 · 11-25
来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投
翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐
瑞恩资本Ryanbe... · 11-25
翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐
泰格医药新注册《泰格医药SPS中心合同管理软件V1.0》项目的软件著作权
证券之星 · 11-25
泰格医药新注册《泰格医药SPS中心合同管理软件V1.0》项目的软件著作权
泰格医药新注册《泰格医药SEDS受试者管理系统V1.0》等2个项目的软件著作权
证券之星 · 11-24
泰格医药新注册《泰格医药SEDS受试者管理系统V1.0》等2个项目的软件著作权
11月22日泰格医药跌5.50%，中欧医疗健康混合A基金重仓该股
证券之星 · 11-22
11月22日泰格医药跌5.50%，中欧医疗健康混合A基金重仓该股
泰格医药(03347)下跌5.15%，报32.25元/股
金融界 · 11-22
泰格医药(03347)下跌5.15%，报32.25元/股
公司概况
公司名称：
杭州泰格医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2012-08-17
主营业务：
杭州泰格医药科技股份有限公司专注于为新药研发提供临床试验全过程专业服务的合同研究组织(CRO)，为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。主要产品为临床试验技术服务、临床试验相关服务及实验室服务等。公司是中国领先的综合生物制药研发服务提供商,且全球的影响力正在不断扩大。
发行价格：
37.88
{"stockData":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":59.17,"timestamp":1734937437000,"preClose":60.9,"halted":0,"volume":9018448,"delay":0,"floatShares":567000000,"shares":865000000,"eps":1.1084,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.73,"latestTime":"12-23 15:00:00","open":61,"high":61.5,"low":59,"amount":540000000,"amplitude":0.0411,"askPrice":59.18,"askSize":5,"bidPrice":59.17,"bidSize":206,"shortable":0,"etf":0,"ttmEps":1.1084,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":60.9,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":66.99,"lowLimit":54.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":864948570,"pbRate":2.5,"roa":"--","roe":"3.85%","epsLYR":2.34,"committee":0.137157,"marketValue":51179000000,"floatMarketCap":33572000000,"peRate":53.383256,"changeRate":-0.0284,"turnoverRate":0.0159,"status":1},"requestUrl":"/m/hq/s/300347/wiki","defaultTab":"wiki","newsList":[{"id":"2493755367","title":"海金格IPO投研报告：CRO遇冷为何业绩逆势增长？北交所两问真实合理性","url":"https://stock-news.laohu8.com/highlight/detail?id=2493755367","media":"时代周报-时代在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493755367?lang=zh_cn&edition=full","pubTime":"2024-12-23 19:30","pubTimestamp":1734953400,"startTime":"0","endTime":"0","summary":"2024年年中，海金格的IPO申报获北交所受理；12月12日，海金格回复了北交所的第二轮问询函。2024年上半年，三家同行可比公司扣非归母净利润均出现下滑，海金格却逆势高速增长，北交所连续两轮问询其业绩增长的真实合理性。海金格拟新增网点与部分分公司存在重合，但各地分公司现有人员数量较少，北交所询问新增网点是否存在闲置风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-23/doc-ineancvn9227140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","LU1820825898.SGD","BK1576","BK1583","LU1146622755.USD","BK1141","BK0028","BK0174","301333","BK0276","300347","301257","BK0216","688710","601066","BK0077"],"gpt_icon":0},{"id":"2492236164","title":"泰格医药控股子公司为其他控股孙公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2492236164","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492236164?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:20","pubTimestamp":1734567600,"startTime":"0","endTime":"0","summary":" 泰格医药发布公告，公司控股孙公司合亚医药科技（上海）有限公司因业务发展需要，拟向境内工商银行申请办理总金额不超过人民币500万元的授信业务，用以补充公司经营资金。公司控股子公司方达医药技术（上海）有限公司拟为上述授信业务提供连带责任保证，本次担保金额不超过人民币500万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-19/doc-inczxzyc7068619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK0028","300347","BK0077","BK1576","BK0216","BK0174","03347","BK1141","LU1820825898.SGD","LU1146622755.USD"],"gpt_icon":0},{"id":"2492188355","title":"泰格医药(03347)控股子公司为其他控股孙公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492188355?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:49","pubTimestamp":1734526161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，公司控股孙公司合亚医药科技(上海)有限公司(以下简称“上海合亚”)因业务发展需要，拟向境内工商银行申请办理总金额不超过人民币500万元的授信业务，用以补充公司经营资金。公司控股子公司方达医药技术(上海)有限公司(以下简称“方达上海”)拟为上述授信业务提供连带责任保证，本次担保金额不超过人民币500万元。本次控股子公司方达上海为控股孙公司上海合亚提供担保是为满足其日常业务进一步的发展需要，担保对象为公司合并报表范围内的控股子公司，风险可控，符合公司利益，不会对公司的正常运作和业务发展产生不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","300347","BK1141","03347","BK0028","BK0077","BK1576","BK0216","LU1146622755.USD","LU1820825898.SGD","BK0174"],"gpt_icon":0},{"id":"2489609408","title":"泰格医药涨5.22%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2489609408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489609408?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:09","pubTimestamp":1733472594,"startTime":"0","endTime":"0","summary":"今日泰格医药涨5.22%，收盘报66.5元。2024年11月3日，开源证券研究员余汝意,聂媛媛发布了对泰格医药的研报《公司信息更新报告：营收环比改善，新签订单持续向好》，该研报对泰格医药给出“买入”评级。研报中预计2024-2026年归母净利润为12.99/16.26/18.17亿元，对应EPS为1.50/1.88/2.1元，当前股价对应PE为41.6/33.3/29.8倍，考虑公司作为国内临床CRO龙头竞争力较强，维持“买入”评级。泰格医药个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600026028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","03347","300347"],"gpt_icon":0},{"id":"2489429187","title":"港股医药外包概念股集体冲高，药明康德(02359.HK)涨超10%，药明生物(02269.HK)涨超8%，昭衍新药(06127.","url":"https://stock-news.laohu8.com/highlight/detail?id=2489429187","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489429187?lang=zh_cn&edition=full","pubTime":"2024-12-06 11:28","pubTimestamp":1733455704,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0348735423.USD","06127","LU0456842615.SGD","LU1880383366.USD","LU0348825331.USD","BK0077","LU2488822045.USD","LU1997245094.SGD","BK0028","03347","LU0326950275.SGD","BK1141","LU0979878070.USD","LU0456827905.SGD","LU0359201612.USD","LU0516422366.SGD","LU0052750758.USD","BK1589","LU1242518931.SGD","BK0216","603259","LU0051755006.USD","LU2045819591.USD","LU0320764599.SGD","LU1720050803.USD","BK0174","LU0140636845.USD","BK1576","02269","LU2242644610.SGD","IE00B0JY6N72.USD","LU0043850808.USD","03759","LU0516423091.SGD","LU0572944931.SGD","159718","LU0181495838.USD","BK1521","BK1583","300347","603127","LU0307460666.USD","LU0417516738.SGD","300759","LU1046422090.SGD","LU0516422440.USD","LU1794554557.SGD","02359","LU0588546209.SGD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2489442014","title":"泰格医药（300347）12月5日主力资金净卖出498.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489442014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489442014?lang=zh_cn&edition=full","pubTime":"2024-12-06 09:24","pubTimestamp":1733448246,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月5日收盘，泰格医药报收于63.2元，下跌0.89%，换手率0.93%，成交量5.28万手，成交额3.34亿元。近5日资金流向一览见下表：泰格医药融资融券信息显示，融资方面，当日融资买入3559.12万元，融资偿还2275.27万元，融资净买入1283.86万元。泰格医药主营业务：临床试验技术服务和临床试验相关服务及实验室服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600008991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0028","BK0077","LU1820825898.SGD","BK0216","300347","LU1146622755.USD","BK1141","BK1583","03347","BK0174"],"gpt_icon":0},{"id":"2488814168","title":"泰格医药(03347)截至11月末累计回购365.52万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488814168","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488814168?lang=zh_cn&edition=full","pubTime":"2024-12-04 18:00","pubTimestamp":1733306417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)公布股份回购进展，截至 2024 年 11 月 30 日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份365.52万股，占公司总股本的比例为0.4226%，占公司A股总股本比例为0.4927%，最高成交价为55.30 元/股，最低成交价为48.17 元/股，成交总金额为约1.91亿元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","399300","BK0174","LU1146622755.USD","03347","300347","BK0077","BK0028","BK0216","BK1141","BK1583","LU1820825898.SGD","BK1576"],"gpt_icon":0},{"id":"2488715768","title":"泰格医药：已回购365.52万股 成交总金额约1.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488715768","media":"中国财富通","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488715768?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:21","pubTimestamp":1733304112,"startTime":"0","endTime":"0","summary":"中国财富通12月4日 - 泰格医药（300347）公告称，截至2024年11月30日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份3,655,200股，占公司总股本的比例为0.4226%，占公司A股总股本比例为0.4927%，最高成交价为55.30元/股，最低成交价为48.17元/股，成交总金额为191,146,104.89元（不含交易费用）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=%2FE%2B0wY4tkfs%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU1820825898.SGD","BK0216","BK1583","BK1576","03347","300347","BK0077","BK0174","BK0028","LU1146622755.USD"],"gpt_icon":0},{"id":"2488915590","title":"泰格医药(300347.SZ)累计回购365.52万股 耗资1.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488915590","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488915590?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:05","pubTimestamp":1733299552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(300347.SZ)公告，截至2024年11月30日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份365.52万股，占公司总股本的比例为0.4226%，占公司A股总股本比例为0.4927%，最高成交价为55.30元/股，最低成交价为48.17元/股，成交总金额为1.91亿元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1141","03347","BK0174","BK1576","BK0216","300347","BK0077","BK1583","LU1820825898.SGD","LU1146622755.USD"],"gpt_icon":0},{"id":"2487305247","title":"泰格医药(03347)上涨5.14%，报34.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2487305247","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487305247?lang=zh_cn&edition=full","pubTime":"2024-11-29 11:56","pubTimestamp":1732852578,"startTime":"0","endTime":"0","summary":"11月29日，泰格医药(03347)盘中上涨5.14%，截至11:56，报34.75元/股，成交3374.24万元。杭州泰格医药科技股份有限公司是一家提供全周期生物医药研发服务的公司，主要为全球制药和医疗器械行业提供创新研发解决方案。公司通过其100多家子公司，打造了一个覆盖全产业链的创新生态，致力于解决全球健康问题，满足患者的医疗需求。截至2024年三季报，泰格医药营业总收入50.68亿元、净利润8.13亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/29115645829484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0174","BK0216","BK1141","LU1146622755.USD","BK0028","BK1576","300347","BK1583","LU1820825898.SGD","BK0077","03347"],"gpt_icon":0},{"id":"2486131668","title":"港股生物医药股午后放量大涨，科伦博泰生物(06990.HK)张近10%，诺诚健华(09969.HK)涨超8.5%，百济神州(06160.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486131668","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486131668?lang=zh_cn&edition=full","pubTime":"2024-11-27 15:16","pubTimestamp":1732691817,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09995","161726","BK1576","LU1969619763.USD","BK4505","688428","03347","LU0307460666.USD","LU1064131003.USD","BK0028","688331","BK0239","LU1146622755.USD","BGNE","LU2148510915.USD","BK4585","SG9999014674.SGD","06990","BK0077","06160","BK0216","BK1141","BK1588","BK4504","BK4588","HSCEI","688235","300347","BK0174","LU1820825898.SGD","BK4535","BK1583","HSTECH","02268","399441","09969","YANG","BK4139","BK1161","LU1064130708.USD","BK4548","LU2328871848.SGD","BK1574","BK4526","07226","LU0196878994.USD","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2486890823","title":"泰格医药(03347)上涨5.25%，报34.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486890823","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486890823?lang=zh_cn&edition=full","pubTime":"2024-11-27 14:25","pubTimestamp":1732688737,"startTime":"0","endTime":"0","summary":"11月27日，泰格医药(03347)盘中上涨5.25%，截至14:25，报34.1元/股，成交5344.04万元。杭州泰格医药科技股份有限公司是一家提供全周期生物医药研发服务的公司，主要为全球制药和医疗器械行业提供创新研发解决方案。公司通过其100多家子公司，打造了一个覆盖全产业链的创新生态，致力于解决全球健康问题，满足患者的医疗需求。截至2024年三季报，泰格医药营业总收入50.68亿元、净利润8.13亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/27142545738767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1820825898.SGD","BK0077","BK1583","300347","03347","BK1576","BK0174","BK1141","LU1146622755.USD","BK0216","BK0028"],"gpt_icon":0},{"id":"2486989019","title":"泰格医药(03347)股价上升5.093%，现价港币$34.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2486989019","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486989019?lang=zh_cn&edition=full","pubTime":"2024-11-27 14:25","pubTimestamp":1732688700,"startTime":"0","endTime":"0","summary":"[上升股]泰格医药(03347) 股价在下午02:25比前收市价上升5.093%，现股价为港币$34.05。至目前为止，今日最高价为$34.05，而最低价为$32.35。总成交量为158.89万股，总成交金额为港币$5.319千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2411271651/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0077","BK1576","BK1583","BK0216","LU1820825898.SGD","BK1141","BK0028","BK0174","03347","300347","LU1146622755.USD"],"gpt_icon":0},{"id":"2486898474","title":"CRO概念股早盘回暖 金斯瑞生物科技涨逾4%泰格医药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486898474","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486898474?lang=zh_cn&edition=full","pubTime":"2024-11-27 11:54","pubTimestamp":1732679640,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n CRO概念股早盘回暖，金斯瑞生物科技（01548）上涨3.82%，报10.88港元；泰格医药（03347）上涨3.40%，报33.50港元；方达控股（01521）上涨2.75%，报1.12港元；昭衍新药（06127）上涨2.06%，报9.43港元；药明生物（02269）上涨0.98%，报14.14港元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-27/doc-incxnmts3655707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320223.HKD","BK0216","HK0000306685.HKD","HK0000306701.USD","BK0077","BK0174","BK1141","BK1583","LU1146622755.USD","300347","LU1820825898.SGD","BK1576","BK0028","HK0000320264.USD","01548","03347"],"gpt_icon":0},{"id":"2486709868","title":"来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709868","media":"活报告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486709868?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:14","pubTimestamp":1732529640,"startTime":"0","endTime":"0","summary":"LiveReport获悉，来自武汉的翰思艾泰生物医药科技（武汉）股份有限公司于2024年11月24日在港交所递交上市申请，拟香港主板上市，这是该公司第1次递交上市申请，独家保荐人为工银国际。截至最后实际可行日期，正在澳大利亚启动用于治疗晚期实体瘤恶性肿瘤的I/IIa期临床研究，并取得国家药监局就其在中国的临床研究的受理通知。截至2024年6月30日，公司账上现金1.5亿元。预计2031年全球肿瘤免疫疗法市场将占全球肿瘤药物市场份额的50.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2024-11-25/doc-incxhqmk8163822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0216","BK0060","BK1576","LU1146622755.USD","BK0077","03347","LU1820825898.SGD","BK1583","300558","300347","BK0174","BK1141","BK0239"],"gpt_icon":0},{"id":"2486372701","title":"翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2486372701","media":"瑞恩资本Ryanbe...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486372701?lang=zh_cn&edition=full","pubTime":"2024-11-25 13:52","pubTimestamp":1732513920,"startTime":"0","endTime":"0","summary":"2024年11月24日，来自湖北武汉的翰思艾泰生物科技(武汉)股份有限公司Hanx Biopharmaceuticals Co., Ltd.在港交所递交招股书，拟香港主板IPO上市。翰思艾泰的核心产品HX009是一种自主研发的PD-1/SIRPα双功能抗体融合蛋白，目前已在澳大利亚及中国完成HX009的I期临床试验。翰思艾泰已完成根据国家药监局批准对HX301进行的I期临床研究，并计划开展HX301与替莫唑胺联用治疗脑胶质母细胞瘤的II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-25/doc-incxhcvq8260278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300558","BK0216","BK1576","BK0028","LU1820825898.SGD","300347","BK0077","HK0000306685.HKD","BK0174","BK0060","600133","BK0277","LU1146622755.USD","01548","BK1141","HK0000306701.USD","BK0086","HK0000320264.USD","BK1583","BK0102","HK0000320223.HKD","BK0239","BK0075"],"gpt_icon":0},{"id":"2486790673","title":"泰格医药新注册《泰格医药SPS中心合同管理软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2486790673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486790673?lang=zh_cn&edition=full","pubTime":"2024-11-25 01:07","pubTimestamp":1732468031,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药（300347）新注册了《泰格医药SPS中心合同管理软件V1.0》项目的软件著作权。今年以来泰格医药新注册软件著作权25个，较去年同期减少了3.85%。结合公司2024年中报财务数据，今年上半年公司在研发方面投入了1.25亿元，同比减2.65%。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500000183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","03347","LU1146622755.USD","BK1141","BK1576","LU1820825898.SGD","300347","BK0216","BK0028","BK0174","BK1583"],"gpt_icon":0},{"id":"2485785667","title":"泰格医药新注册《泰格医药SEDS受试者管理系统V1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2485785667","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485785667?lang=zh_cn&edition=full","pubTime":"2024-11-24 01:11","pubTimestamp":1732381871,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰格医药（300347）新注册了2个项目的软件著作权，包括《泰格医药SEDS受试者管理系统V1.0》、《泰格智能语音转文本训练软件V1.0》等。今年以来泰格医药新注册软件著作权22个，较去年同期减少了15.38%。结合公司2024年中报财务数据，今年上半年公司在研发方面投入了1.25亿元，同比减2.65%。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112400000062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0216","BK1141","LU1146622755.USD","BK0028","BK1576","300347","BK1583","LU1820825898.SGD","BK0077","03347"],"gpt_icon":0},{"id":"2485923309","title":"11月22日泰格医药跌5.50%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485923309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485923309?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:29","pubTimestamp":1732264194,"startTime":"0","endTime":"0","summary":"证券之星消息，11月22日泰格医药跌5.50%，收盘报61.33元，换手率1.66%，成交量9.43万手，成交额5.94亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共131家，其中持有数量最多的公募基金为中欧医疗健康混合A。中欧医疗健康混合A目前规模为184.44亿元，最新净值1.6701，较上一交易日下跌0.42%，近一年下跌16.35%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200026081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","300347","BK1141","03347","BK0028","BK0077","BK1576","BK0216","159760","LU1146622755.USD","LU1820825898.SGD","BK0174"],"gpt_icon":0},{"id":"2485288263","title":"泰格医药(03347)下跌5.15%，报32.25元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485288263","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485288263?lang=zh_cn&edition=full","pubTime":"2024-11-22 13:41","pubTimestamp":1732254092,"startTime":"0","endTime":"0","summary":"11月22日，泰格医药(03347)盘中下跌5.15%，截至13:41，报32.25元/股，成交3474.96万元。杭州泰格医药科技股份有限公司是一家提供全周期生物医药研发服务的公司，主要为全球制药和医疗器械行业提供创新研发解决方案。公司通过其100多家子公司，打造了一个覆盖全产业链的创新生态，致力于解决全球健康问题，满足患者的医疗需求。截至2024年三季报，泰格医药营业总收入50.68亿元、净利润8.13亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/22134145567256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0174","LU1146622755.USD","03347","300347","BK0077","BK0028","BK0216","BK1141","BK1583","LU1820825898.SGD","BK1576"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-08-17","address":"浙江省杭州市滨江区西兴街道聚工路19号8幢20层2001-2010室","stockEarnings":[{"period":"1week","weight":-0.0262},{"period":"1month","weight":-0.066},{"period":"3month","weight":0.2136},{"period":"6month","weight":0.2125},{"period":"1year","weight":0.1488},{"period":"ytd","weight":0.1209}],"companyName":"杭州泰格医药科技股份有限公司","boardCode":"AI0073","perCapita":"--","boardName":"研究和试验发展","registeredCapital":"86494万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 杭州泰格医药科技股份有限公司专注于为新药研发提供临床试验全过程专业服务的合同研究组织(CRO)，为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。主要产品为临床试验技术服务、临床试验相关服务及实验室服务等。公司是中国领先的综合生物制药研发服务提供商,且全球的影响力正在不断扩大。","serverTime":1734957236639,"listedPrice":37.88,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,300347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(300347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(300347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}